Eyenovia Inc.

Eyenovia Inc. is a biotechnology company specializing in the development of advanced therapies for eye-related conditions. Its core focus is on creating microdose treatments that utilize its unique microdosing technology, aimed at improving the precision and safety of ocular drug administration. This technology promises to enhance treatment efficacy while minimizing side effects, offering a significant advancement in the field of ophthalmology. Eyenovia Inc. is particularly impactful in sectors tackling chronic eye diseases, including presbyopia and myopia progression, contributing to innovations in how these conditions are managed. Headquartered in New York, the company plays a vital role in the niche market of ophthalmic therapies, positioning itself as a pioneer in transforming traditional eye care treatments into more effective and patient-friendly solutions. Through strategic collaborations and continuous research, Eyenovia strives to revolutionize how ophthalmic medications are delivered, showcasing its commitment to advancing eye health technology.